Helix Financial Statements From 2010 to 2025
| HBPCF Stock | USD 1.73 0.00 0.00% |
Check Helix BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Helix BioPharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Helix financial statements analysis is a perfect complement when working with Helix BioPharma Valuation or Volatility modules.
Helix |
Helix BioPharma Corp Company Current Valuation Analysis
Helix BioPharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Helix BioPharma Current Valuation | 30.65 M |
Most of Helix BioPharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Helix BioPharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Helix BioPharma Corp has a Current Valuation of 30.65 M. This is 99.79% lower than that of the Biotechnology sector and 99.34% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.82% higher than that of the company.
Helix BioPharma Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Helix BioPharma competition to find correlations between indicators driving Helix BioPharma's intrinsic value. More Info.Helix BioPharma Corp is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Helix BioPharma's earnings, one of the primary drivers of an investment's value.About Helix BioPharma Financial Statements
Helix BioPharma stakeholders use historical fundamental indicators, such as Helix BioPharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Helix BioPharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Helix BioPharma's assets and liabilities are reflected in the revenues and expenses on Helix BioPharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Helix BioPharma Corp. Please read more on our technical analysis and fundamental analysis pages.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. HELIX BIOPHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Helix Pink Sheet
Helix BioPharma financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.